Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update
02 août 2016 16h05 HE
|
Prothena Corporation Plc
Net cash used in operating and investing activities was $32.3 million in the second quarter and $57.7 million for the first six months of 2016; strong quarter-end cash and restricted cash position...
Prothena to Participate in Cantor Fitzgerald’s 2nd Annual Healthcare Conference
06 juil. 2016 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, July 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis
05 juil. 2016 07h00 HE
|
Prothena Corporation Plc
New data from Phase 1/2 dose-escalation (n=27) and expansion (n=42) study show best response rates in total cardiac- and renal- evaluable patients of 53% and 63%, respectively, that are consistent...
Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses
21 juin 2016 16h05 HE
|
Prothena Corporation Plc
New clinical data to be presented from Phase 1/2 dose-escalation and expansion trial of NEOD001 for the potential treatment of AL amyloidosisPresentations to highlight data from clinical,...
Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
09 juin 2016 16h05 HE
|
Prothena Corporation Plc
All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteersNeutralization of Th17 cells of greater than 95...
Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
23 mai 2016 16h05 HE
|
Prothena Corporation plc
New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosisAdditional presentations to highlight data from preclinical and...
Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
19 mai 2016 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016
09 mai 2016 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update
03 mai 2016 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised...
Data from Prothena’s Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid
16 mars 2016 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 16, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and...